Effectiveness and safety of dexmedetomidine in patients undergoing general anaesthesia: A randomized, single-blind trialAuthor(s):
Dr. Raghunath Ravirala and Dr. Ershad Mohammed SohailAbstract:
Background: During the administration of general anaesthesia, laryngoscopy and endotracheal intubation must be performed. Just before intubation, succinyl choline is given. Intraocular pressure, heart rate, and blood pressure may all rise as a result of this. Many medications have been tried and utilised to mitigate this stress reaction. Dexmedetomidine is a sedative, anxiolytic, and analgesic since it is an alpha2 adrenergic agonist.
Methods: For this study, researchers utilised a randomised, single-blind, placebo-controlled design. Treatment was provided by the Anaesthesiology Division at Meenakshi Medical College Hospital & Research Institute, Kancheepuram, Tamil Nadu, India between July 2020 to June 2021. A no of patients used was 60 was utilised, with 30 participants in each of two groups.
Results: Adjustments to IOP, HR, MAP, and sedation were evaluated between the two groups in this single-blind randomised trial. In the group that received the optimal dosage of dexmedetomidine, intraocular pressure (IOP) was significantly lowered, and the expected increase in IOP due to intubation was avoided. Additionally, the pressor response to laryngoscopy and endotracheal intubation was greatly diminished.
Conclusion: With the current trial design, premedication with intravenous Dexmedetomidine reduces the increase in intraocular pressure that occurs after succinylcholine and intubation. Where intubation and succinylcholine lead to increases in intraocular pressure that are harmful to patients.DOI: 10.22271/27069567.2021.v3.i2i.440Pages: 631-634 | Views: 33 | Downloads: 16Download Full Article: Click Here
How to cite this article:
Dr. Raghunath Ravirala, Dr. Ershad Mohammed Sohail. Effectiveness and safety of dexmedetomidine in patients undergoing general anaesthesia: A randomized, single-blind trial
. Int J Adv Res Med 2021;3(2):631-634. DOI: 10.22271/27069567.2021.v3.i2i.440